FDA 483 - Biomet, Inc. - October 16, 2017

This FDA Form 483 document outlines several significant observations made during an inspection, indicating deficiencies in the facility's quality system and manufacturing processes.

**Key Observations and Violations:**

* **Corrective and Preventive Action (CAPA):** Procedures for CAPA have not been adequately established. This suggests a lack of a systematic approach to identify, investigate, and correct quality problems, and prevent their recurrence. * **Nonconforming Product Control:** Procedures for controlling product that does not conform to specified requirements have not been adequately established. This raises concerns about the potential for defective products to be released or used. * **Packaging and Shipping:** Device packaging and/or shipping containers are not designed and constructed to protect the device from alteration or damage during processing, storage, handling, and distribution. This could lead to product damage or compromise during transit. * **Process Control:** Procedures for monitoring and control of process parameters for a validated process have not been adequately established. This indicates a potential for variability in manufacturing processes, impacting product quality and consistency. * **Software Validation:** Software used as part of the quality system has not been adequately validated for its intended use according to an established protocol. This is a critical finding as unvalidated software can lead to unreliable data and decisions within the quality system. * **Equipment Calibration:** Procedures to ensure equipment is routinely calibrated have not been adequately established. This can result in inaccurate measurements and non-conforming products